Levi Garraway

Dr. Levi Garraway, MD, PhD, presently serves as EVP, Head of Product Development, and Chief Medical Officer at Genentech and Roche, a position he has held since 2019. He was most recently Eli Lilly’s Senior Vice President, Oncology Research and Development & Lilly Research Laboratories Novel Target Research. He joined Eli Lilly in 2017 as Senior Vice President, Global Development and Medical Affairs for their Oncology division. Prior to that, Dr. Garraway was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals including the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and the Broad Institute of MIT and Harvard. He was

also co-leader of the Cancer Genetics Program at the Dana-Farber / Harvard Cancer Center. In

2010, Dr. Garraway co-founded Foundation Medicine, the world’s leading provider of tumor

molecular information. A Fellow of the American Association for Cancer Research (AACR), over the course of his career Dr. Garraway has served on the advisory boards of major cancer centers including Memorial Sloan Kettering and MD Anderson. He also served on several major National Institutes of Health (NIH) committees as well as the Blue Ribbon Panel for the Beau Biden Cancer Moonshot Initiative. Dr. Garraway was president of the American Society of Clinical Investigation from 2014 - 2015. He is the author of nearly 200 peer-reviewed scientific articles and has received many awards, including the

Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from the AACR, the New

Innovator Award from the NIH, and an Outstanding Investigator Award from the National Cancer Institute. Dr. Garraway is a graduate of Harvard, where he earned his A.B., M.D., and his Ph.D. in Biological Chemistry and Molecular Pharmacology.